Drug Trial Radar · NCT07818499
A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma
Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
204
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
- First posted
- Sep 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase Ib/II study is a clinical trial to explore the efficacy and safety of BL-M08D1 for injection in combination with immunochemotherapy in patients with diffuse large B-cell lymphoma.
Conditions
- Diffuse Large B-Cell Lymphoma
Interventions
BL-M08D1Drug
Administration by intravenous infusion for a cycle of 3 weeks.
RituximabDrug
Administration by intravenous infusion for a cycle of 3 weeks.
Gemcitabine HydrochlorideDrug
Administration by intravenous infusion for a cycle of 3 weeks.
OxaliplatinDrug
Administration by intravenous infusion for a cycle of 3 weeks.
CyclophosphamideDrug
Administration by intravenous infusion for a cycle of 3 weeks.
Doxorubicin Hydrochloride LiposomeDrug
Administration by intravenous infusion for a cycle of 3 weeks.
Vincristine SulfateDrug
Administration by intravenous infusion for a cycle of 3 weeks.
Prednisone Acetate TabletsDrug
Oral administration for a cycle of 3 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended Phase II Dose (RP2D)Time frame: Up to approximately 24 months
- Objective Response Rate (ORR)Time frame: Up to approximately 24 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.